April 12, 2011Open Access

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

Key Points

Key points are not available for this paper at this time.

Abstract

Decitabine administered in 6-week cycles is active in older patients with higher-risk MDS, resulting in improvements of OS and AMLFS (nonsignificant), of PFS and AML transformation (significant), and of QOL. Short MDS duration was an independent adverse prognosticator.

Bookmark

View Full Paper

Cite This Study

Lübbert et al. (Tue,) studied this question.

synapsesocial.com/papers/69ecef1dd55980bedc8fe5b4 https://doi.org/https://doi.org/10.1200/jco.2010.30.9245

Bookmark

View Full Paper